Black Farmers in Brazil Changing Views on Coffee Production

Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP
Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP
TT

Black Farmers in Brazil Changing Views on Coffee Production

Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP
Many in Brazil still associate coffee production with slavery. Douglas Magno / AFP

Raphael Brandao beams with pride as he describes the high-end Brazilian coffee he produces with beans sourced exclusively from Black farmers in a country where many still associate the product with slavery.
The 31-year-old buys his coffee beans solely from farms owned by Afro-descendents and says his goal is to "reverse this logic that Black people" like himself "are mere laborers”.
"In my own way, I am trying to make historical reparations," Brandao told AFP at his roastery in Nova Iguacu, a poor suburb of Rio de Janeiro.
Four years ago, he launched his brand Cafe di Preto.
By 2022 he sold 800 kilograms (about 1,700 pounds), the following year 1.4 tons. This year he hopes to increase that to more than two tons following a 20-percent sales increase in the first quarter alone.
The logo for Cafe di Preto is a raised Black fist clutching a coffee branch, and the different flavor lines are each named after important Black women of Brazilian history.
Brazil was the last country in the Americas to abolish slavery, in 1888, and racial inequalities remain high in a country where more than half of people identify as "preto" (Black) or mixed-race.
'Changing the world'
He is also seeking to "break the stigma that Black people do not produce quality."
"So my work also gives light to this," he said. "Today I have six coffees produced by Black people, all of them... of great quality."
Many of his clients, he added, are looking for quality but also for a product that is "changing the world."
Brandao is a leader in the so-called Black Business wave in Brazil that promotes commerce among people of African descent as a tool for social progress.
At first, he had trouble finding Black suppliers given that the overwhelming majority of coffee plantations in Brazil still belong to white families.
"My black suppliers are the first generation to produce on their own land, often only a few hectares," he said.
And Brandao has more than once had to defend his chosen crusade.
"I am sometimes asked: 'What if it was the opposite, if roasteries owned by whites bought coffee from white farmers?' But isn't that what is happening already?"
From farm to cup
About 500 kilometers (311 miles) from Nova Iguacu is the 19-hectare (47-acre) coffee plantation of Neide Peixoto, one of Brandao's first suppliers.
"I have been in contact with coffee since childhood. My parents worked in crops and I often accompanied them," Peixoto, 49, told AFP on her farm in the southeastern state of Minas Gerais, a mecca for coffee production.
Unlike her parents, she grows coffee on land that belongs to her own family, bought by her husband and brothers who are also former laborers.
"It means a lot to me to be a Black producer of special coffee, because... we, Black people, have a very difficult and painful history," Peixoto said.
Most of the farm's production is for export, but the beans reserved for Cafe di Preto have a special significance for Peixoto.
"It's exciting to know that the coffee I produce, which is coffee produced by Black people, is also roasted by Black people," she said.
"I'm very happy to know that we are making this connection, from production here on the farm to the cup."



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”